Kanna vs Kratom: What's the Difference
Share
If you've been exploring natural botanicals for general wellbeing, you've likely come across both kanna (Sceletium tortuosum) and kratom (Mitragyna speciosa). On the surface they seem similar — both are plant-based, both have a long history of traditional use, and both attract people curious about what nature has to offer beyond conventional options.
But they are fundamentally different plants with different chemistry, different traditional uses, and very different legal situations across Europe. This guide breaks down what is currently known about both, so you can make an informed decision.
What Is Kanna (Sceletium tortuosum)?
Kanna is a succulent plant native to South Africa, used for centuries by the indigenous San and Khoikhoi peoples. Traditionally it was fermented and chewed during long hunts and social gatherings, and is well-documented in ethnobotanical literature as a plant with deep cultural significance in southern Africa.
The active compounds in kanna are alkaloids — primarily mesembrine, mesembronone, and delta-7-mesembrenone. Research into these alkaloids is ongoing, and scientists have identified two mechanisms of particular interest:
Serotonin Reuptake Inhibition (SRI): Early research suggests mesembrine may interact with serotonin transporters in a manner similar in principle to how certain classes of compounds affect serotonin availability. This area of research is still developing and no clinical conclusions should be drawn from it.
PDE4 Inhibition: Research has also explored mesembrine's potential interaction with phosphodiesterase-4 (PDE4), an enzyme involved in various neurological processes. PDE4 inhibition is an active area of scientific interest. Again, this is preliminary research and not a basis for health claims.
Modern standardized extracts like MT55 and MZ0 concentrate these alkaloids to verified percentages, allowing for consistent, measurable dosing — something traditional use never offered.
What Is Kratom (Mitragyna speciosa)?
Kratom is a tropical tree from Southeast Asia, primarily Thailand, Indonesia, and Malaysia, where its leaves have historically been used by agricultural workers. The active compounds are mitragynine and 7-hydroxymitragynine, which have been studied for their interactions with opioid receptors in the brain.
This opioid receptor activity is what makes kratom both notable and controversial among researchers and regulators. It is fundamentally different chemistry from kanna and carries a very different profile of documented risks.
The Key Differences: A Direct Comparison
Mechanism of Action
This is the most important distinction. Research suggests kanna alkaloids may interact with serotonin and PDE4 pathways. Kratom alkaloids have been studied primarily for their opioid receptor interactions. These are entirely different systems, and the distinction matters significantly when considering safety and dependency potential.
Traditional and Reported Use
Kanna has a centuries-long ethnobotanical record of use in southern African cultures. In contemporary contexts, users commonly report experiences of general relaxation and a sense of calm — though individual responses vary considerably and these are anecdotal accounts, not clinically verified outcomes.
Kratom has its own traditional history in Southeast Asia. Contemporary users report a wide range of experiences depending on dose and variety. At lower doses some report stimulating effects; at higher doses sedating effects are more commonly described. As with kanna, these are anecdotal and individual variation is significant.
Dependency and Withdrawal: What Research Shows
This is where the two plants diverge most significantly in the scientific literature.
Kratom has a well-documented dependency profile in research and regulatory literature. Because its active compounds interact with opioid receptors, regular use has been associated with physical dependence in studies and case reports. Withdrawal effects consistent with opioid-class dependence have been reported in the literature. This is a serious consideration documented by researchers and health authorities.
Kanna does not interact with opioid receptors. Its dependency potential is considered low in the available literature. While some users report mild tolerance with frequent use, physical withdrawal comparable to opioid dependence has not been documented in scientific literature.
Legal Status in Europe
This is critical for anyone in Spain or the EU.
Kanna is legal throughout the European Union, including Spain. It is not a controlled substance anywhere in the EU. It can be legally imported, sold, and purchased with no restrictions on possession.
Kratom's legal status in the EU is fragmented and in many places restrictive. It is banned or controlled in several EU member states including Sweden, Denmark, Latvia, Lithuania, Poland, and Romania. In Spain it currently exists in a legal grey area — not explicitly scheduled but under increasing regulatory scrutiny. Across much of Northern Europe purchasing or possessing kratom carries real legal risk.
For anyone in Spain or purchasing within the EU, kanna's consistent legal status across all member states is a meaningful practical distinction.
Safety Considerations
Both plants are used by adults globally, but their safety profiles differ considerably based on available evidence.
Kratom has attracted significant regulatory attention. Documented concerns in the literature include potential for physical dependence, reported liver toxicity with prolonged heavy use, and potentially dangerous interactions with other substances — particularly opioids, benzodiazepines, and alcohol. Several adverse event reports have been published, though almost always involving co-ingestion of other substances.
Kanna's documented safety profile is more limited in scope. The primary known consideration is its potential interaction with serotonergic medications — individuals taking SSRIs, SNRIs, MAOIs, or other compounds that affect serotonin should not combine kanna without consulting a healthcare professional, as interactions may occur. Outside of this consideration, serious adverse events have not been widely reported in the literature at normal amounts.
Neither plant has been evaluated as a medicine or supplement by the European Medicines Agency or EFSA, and nothing in this article should be interpreted as medical advice.
Onset and Duration
Based on user reports, kanna extract effects are typically described as beginning within 20–45 minutes and lasting 2–4 hours, with a gradual onset and offset.
Kratom effects are typically reported to begin within 15–30 minutes, with durations of 4–6 hours or more at higher amounts. Individual variation is significant with both plants.
Who Might Be Interested in Each Plant?
This is an informational comparison — not a recommendation. That said, the documented differences between the two plants suggest different profiles of interest.
Kanna may be of interest to those exploring:
- Botanicals with a long, well-documented ethnobotanical history
- Plants with a cleaner legal status across all EU countries
- Compounds being researched for serotonin and PDE4 interactions
- Options with a lower documented dependency profile
- Botanicals compatible with an active daily lifestyle
Kratom tends to attract interest from those familiar with:
- Opioid receptor pharmacology
- Stronger sedating or analgesic effects
- Plants with a history of use in Southeast Asian traditional medicine
Given kratom's legal uncertainty in much of the EU, documented dependency risks, and more complex interaction profile, kanna represents a more straightforward option for most people in Spain and Europe exploring this category of botanicals.
Understanding Kanna Extract Types: MT55 vs MZ0
If you decide to explore kanna, you'll encounter different extract designations. MT55 and MZ0 are the two most widely available standardized extracts and they differ meaningfully in their alkaloid profiles.
MZ0 typically shows a higher mesembrine ratio — around 85% of total alkaloids — with lower mesembronone. Users who have tried both often describe MZ0 as having a cleaner, more uplifting character. Many report preferring it during the day.
MT55 has a higher mesembronone content — around 22% compared to roughly 13% in MZ0. Mesembronone is the subject of separate research interest. Users commonly describe MT55 as having a more settling, calming quality and tend to prefer it for evening use or in situations where relaxation is the primary interest.
These are user-reported distinctions. Individual responses vary and no clinical outcomes are implied.
When purchasing any kanna extract, always look for a published Certificate of Analysis (COA) from a third-party laboratory confirming the alkaloid profile and testing for pesticides, heavy metals, and microbial contamination. This is the minimum standard for any serious supplier.
A Note on Dosing Kanna Extract
Because this article addresses standardized extracts specifically, dosing differs from traditional plant use. For a 5% standardized extract, amounts commonly referenced in user communities start in the range of 25–50mg, with more experienced users sometimes using 50–100mg. Starting conservatively and assessing individual response is always advisable.
This is not a dosing recommendation. Individual responses vary and no amount has been clinically validated for any health outcome.
Summary
Kanna and kratom are not comparable alternatives. They have different chemistry, different traditional histories, different risk profiles, and critically — very different legal standing across the EU.
For those in Spain and Europe curious about the growing category of traditional botanicals, kanna presents a well-documented, legally straightforward, and lower-risk profile based on available evidence. Its effects are subtler than kratom's — and for most people exploring general botanical wellness, that is precisely the point.
Kratom's stronger interaction profile comes with meaningfully greater risks and significant legal uncertainty across EU member states. For general wellness exploration, those tradeoffs warrant serious consideration.
If you are curious about kanna, sourcing from a supplier with full batch-level laboratory testing and published COAs is essential. The quality difference between a verified standardized extract and an unverified product is significant.
Sceletic Co. sources its Sceletium tortuosum extracts directly from licensed producers in South Africa, with full batch-level laboratory testing and published Certificates of Analysis for every batch. MT55 and MZ0 extracts are available for delivery across Spain and the EU.
Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. Kanna extracts sold by Sceletic Co. are raw botanical specimens intended for research and educational purposes only, and are not intended for human consumption, nor sold as food supplements or medicines. Always consult a qualified healthcare professional before using any botanical product, particularly if you are taking prescription medications or have an existing health condition. Nothing in this article has been evaluated by the European Food Safety Authority or any medicines regulatory body.